Crestline Management’s Gilead Sciences GILD Stock Holding History

Crestline Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-46,779	Closed	-$4.32M	–	253
2024 Q4	$4.32M	Buy	46,779 +5,875	+14%	+$529K	0.14%	160
2024 Q3	$3.43M	Buy	+40,904	New	+$3.12M	0.18%	139
2019 Q4	–	Sell	-50,000	Closed	-$3.17M	–	66
2019 Q3	$3.17M	Buy	50,000 +32,000	+178%	+$2.09M	0.51%	35
2019 Q2	$1.22M	Buy	+18,000	New	+$1.18M	0.16%	57
2018 Q3	–	Sell	-20,840	Closed	-$1.48M	–	180
2018 Q2	$1.48M	Buy	+20,840	New	+$1.47M	0.16%	168
2017 Q3	–	Sell	-50,881	Closed	-$3.6M	–	144
2017 Q2	$3.6M	Buy	50,881 +28,881	+131%	+$1.92M	0.48%	15
2017 Q1	$1.49M	Buy	+22,000	New	+$1.55M	0.27%	40
2016 Q4	–	Sell	-10,714	Closed	-$848K	–	132
2016 Q3	$848K	Buy	+10,714	New	+$870K	0.11%	100

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Crestline Management's GILD Position: Q1 2025 in Review

Crestline Management sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 46,779 shares — an estimated $4.32M sold.

Crestline Management first reported a position in GILD in Q3 2016 and held it in 8 quarters. The position peaked at $4.32M in Q4 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

Crestline Management reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 46,779 Gilead Sciences shares in Q1 2025, an estimated $4.32M.
Crestline Management first reported a position in Gilead Sciences in Q3 2016 and held it in 8 quarters.
Crestline Management's Gilead Sciences position peaked at $4.32M in Q4 2024.
2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.